ReviewHuman vaccines & immunotherapeutics2017
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A novel approach to designing viral precision vaccines applied to SARS-CoV-2.Frontiers in cellular and infection microbiology · 2024Article
- Review
- Article
- Planetary health & COVID-19: A multi-perspective investigation.One health (Amsterdam, Netherlands) · 2022Review
- Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice.The Journal of veterinary medical science · 2022Article
- Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?Exploration (Beijing, China) · 2022Article
- Recent Update of COVID-19 Vaccines.Advanced pharmaceutical bulletin · 2022Review
- Review
- Review
- Vaccine against SARS-CoV-2: Challenges and considerations.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021Article
- SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.Global heart · 2021Review
- Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.International journal of biological macromolecules · 2020Review
- Cardiac and arrhythmic complications in patients with COVID-19.Journal of cardiovascular electrophysiology · 2020Review
- [Conducting clinical studies during the epidemics of communicable diseases: perspectives of methodology and health economics].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Vaccine against Middle East respiratory syndrome coronavirus.The Lancet. Infectious diseases · 2019Article
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.The Lancet. Infectious diseases · 2019Article
- Article
- Zika Vaccine Development-Current Progress and Challenges for the Future.Tropical medicine and infectious disease · 2019Review
- Review
- Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases.Human vaccines & immunotherapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade and a half has been characterized by numerous emerging infectious diseases. With each new threat, there has been a call for rapid vaccine development. Pathogens such as the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and the Zika virus represent either new viral entities or viruses emergent in new geographic locales and characterized by novel complications. Both serve as paradigms for the global spread that can accompany new pathogens. In this paper, we review the epidemiology and pathogenesis of MERS-CoV and Zika virus with respect to vaccine development. The challenges in vaccine development and the approach to clinical trial design to test vaccine candidates for disease entities with a changing epidemiology are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.